Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733693 · ClinicalTrials.gov registry record · Phase 4
Neurocognitive Effects of Opiate Agonist Treatment
A Phase 4 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 135
- Enrollment target
NCT01733693 is a Phase 4 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 135 participants.
The verdict
NCT01733693, a Phase 4 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to (1) compare the effects of buprenorphine and methadone, two types of opioid addiction treatment, on the ability to think and reason among people addicted to opiates, and who are either HIV negative or HIV positive; and (2) investigate whether HIV infection changes the way opioid treatment affects the ability to think and reason. The investigators hypothesize that there will be (1) significant improvement in thinking and reasoning ability after starting buprenorphine treatment compared to methadone treatment, among participants with and without HIV at 2 and 4 months compared to baseline; and (2) HIV positive participants will demonstrate significant improvement in thinking and reasoning ability at 2 and 4 months compared to baseline, but that their thinking and reasoning ability will still be lower than HIV negative participants.
Interventions
- DRUG Methadone
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01733693
The ClinicalTrials.gov registry entry for NCT01733693 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methadone is the first listed.
NCT01733693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01733693 about?
NCT01733693 is a clinical study titled "Neurocognitive Effects of Opiate Agonist Treatment". The purpose of this study is to (1) compare the effects of buprenorphine and methadone, two types of opioid addiction treatment, on the ability to think and reason among people addicted to opiates, and who are either HIV negative or HIV positive; and (2) investigate whether HIV infection changes the...
What is the current status of trial NCT01733693?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 135 participants. The study started on 2013-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT01733693?
The interventions under investigation include: Methadone (DRUG), Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT01733693?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.